Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM0504 vs Semaglutide as Add-on Therapy in Type 2 Diabetes
NCT06716216Phase 3Active, not recruiting
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Jan 2025
- Primary completion
- Nov 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BGM0504 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoint: Change From Baseline in Hemoglobin A1c (HbA1c) at 32 weeks. Started Jan 2025; status: active, not recruiting.
02
Drugs
BGM0504
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06716216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716216.